A unicorn stalks Wall Street in search of IPO cash; CASI Pharma in-licenses CD19 therapy from China’s Juventas
→ A herd of upstart biotechs will look to Wall Street for some major windfalls this week as a burst of new offerings continues to feed cash into the R&D system. Today we learned that BridgeBio will look to raise in the neighborhood of $225 million by offering 15 million shares for $14 to $16 each. And they have a string of joint bookrunners: J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink, KKR, Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James. If successful, BridgeBio will emerge with a market cap of around $1.7 billion. There are 5 biotechs looking to IPO this week, including Akero and Prevail.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
